Key result
Ro 43-8857 and L-700,462 show species-specific differences in inhibiting platelet aggregation and prolonging bleeding time.
Population
In vitro whole blood from multiple species and in vivo models
Design
Preclinical
Authors
Loading...
Species differences in GP IIb/IIIa antagonist effects caution against direct animal-to-human extrapolation; leaves open optimal preclinical models for antiplatelet development.
The synthetic GP-IIb/IIIa antagonists Ro 43-8857 and L-700,462 exhibit significant species-specific differences in their anti-aggregatory and bleeding effects, highlighting the importance of species and vessel selection in preclinical anti-platelet drug evaluation.
Cook et al. (1993) studied this question. Ro 43-8857 and L-700,462 was evaluated on Platelet aggregation and bleeding time. Ro 43-8857 and L-700,462 demonstrated significant species-specific differences in their ability to inhibit platelet aggregation and prolong bleeding times in guinea-pigs and dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: